Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Venetoclax Monotherapy in Japanese Subjects With Relapsed or Refractory Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma

NCT07387471 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT07387471
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07387471 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Venetoclax Monotherapy in Japanese Subjects With Relapsed or Refractory Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 17, 2026
Completion date
July 31, 2028
Enrollment
14 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoplasmacytic lymphoma, waldenstrom macroglobulinemia